27801735|t|Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study
27801735|a|Blockade of inhibitory immune checkpoints is currently arising as a potential immunologic option for tumor therapy. Inhibition of programmed cell death protein 1 and/or its specific ligand programmed death-ligand 1 (PD-L1) was effective in clinical trials in advanced melanoma, non-small cell lung cancer (NSCLC) bladder and kidney cancer. The predictive role of the immunohistochemical (IHC) expression of PD-L1 is highly debated. Different reagents, clones, cutoffs of cell expression and subjective interpretation of PD-L1 immunoreactivity in epithelial cells and lymphocytes are the main issue. In this study we selected 58 consecutive NSCLC surgical specimens that underwent pathologic examination from January 2014 to July 2015. Using a tissue microarray approach we evaluated the IHC expression of PD-L1 in tumor-infiltrating lymphocytes and tumor cells (TCs) and compared the ICH staining with tumor histology, grade and the age of the tissue blocks. The main new finding was the fading of PD-L1 IHC expression in TCs in tissues processed in 2014 compared with 2015. PD-L1 expression in tumor-infiltrating lymphocytes in the 2 years was similar. We also found a significant higher immunoreactivity of TCs in high grade NSCLC and in the squamous carcinoma histotype compared with low grade tumors and the adenocarcinoma histology (P=0.013). We demonstrated that the IHC evaluation of PD-L1 in NSCLC archival tissues is feasible and can be implemented in a routine pathology setting, but it should be carefully assessed in tissue blocks older than 1 year.
27801735	0	6	Fading	T081	C0205216
27801735	7	16	With Time	T079	C0332311
27801735	20	25	PD-L1	T129	C4300350
27801735	26	42	Immunoreactivity	T044	C0597879
27801735	46	73	Non-Small Cells Lung Cancer	T191	C0007131
27801735	74	81	Tissues	T024	C0040300
27801735	85	105	Methodological Study	T057	C0025662
27801735	106	114	Blockade	T169	C0332206
27801735	118	147	inhibitory immune checkpoints	T043	C1155874
27801735	184	195	immunologic	T169	C0205470
27801735	196	202	option	T169	C1518601
27801735	207	220	tumor therapy	T061	C0920425
27801735	222	232	Inhibition	T052	C3463820
27801735	236	267	programmed cell death protein 1	T116,T129,T192	C2986635
27801735	288	294	ligand	T103	C0023688
27801735	295	320	programmed death-ligand 1	T129	C4300350
27801735	322	327	PD-L1	T129	C4300350
27801735	346	361	clinical trials	T062	C0008976
27801735	365	373	advanced	T080	C0205179
27801735	374	382	melanoma	T191	C0025202
27801735	384	410	non-small cell lung cancer	T191	C0007131
27801735	412	417	NSCLC	T191	C0007131
27801735	419	426	bladder	T191	C0005695
27801735	431	444	kidney cancer	T191	C1378703
27801735	473	492	immunohistochemical	T059	C1441616
27801735	494	497	IHC	T059	C1441616
27801735	499	509	expression	T045	C1171362
27801735	513	518	PD-L1	T129	C4300350
27801735	548	556	reagents	T130	C0034760
27801735	558	564	clones	T024	C1522642
27801735	577	581	cell	T025	C0007634
27801735	582	592	expression	T045	C1171362
27801735	597	607	subjective	T080	C0439655
27801735	608	622	interpretation	T033	C0438231
27801735	626	631	PD-L1	T129	C4300350
27801735	632	648	immunoreactivity	T044	C0597879
27801735	652	668	epithelial cells	T025	C0014597
27801735	673	684	lymphocytes	T025	C0024264
27801735	698	703	issue	T033	C0033213
27801735	746	751	NSCLC	T191	C0007131
27801735	752	770	surgical specimens	T024	C1292533
27801735	786	808	pathologic examination	T060	C4086729
27801735	814	821	January	T080	C3829466
27801735	830	834	July	T080	C3829447
27801735	856	875	microarray approach	T059	C1449575
27801735	893	907	IHC expression	T059	C1441616
27801735	911	916	PD-L1	T129	C4300350
27801735	920	950	tumor-infiltrating lymphocytes	T025	C0079722
27801735	955	966	tumor cells	T025	C0597032
27801735	968	971	TCs	T025	C0597032
27801735	990	1002	ICH staining	T059	C1441616
27801735	1008	1023	tumor histology	T091	C1516204
27801735	1025	1030	grade	T185	C0919553
27801735	1050	1063	tissue blocks	T024	C0040300
27801735	1078	1085	finding	T033	C0243095
27801735	1094	1100	fading	T081	C0205216
27801735	1104	1109	PD-L1	T129	C4300350
27801735	1110	1124	IHC expression	T059	C1441616
27801735	1128	1131	TCs	T025	C0597032
27801735	1135	1142	tissues	T024	C0040300
27801735	1181	1186	PD-L1	T129	C4300350
27801735	1187	1197	expression	T045	C0017262
27801735	1201	1231	tumor-infiltrating lymphocytes	T025	C0079722
27801735	1241	1246	years	T079	C0439234
27801735	1251	1258	similar	T080	C2348205
27801735	1276	1294	significant higher	T080	C1299395
27801735	1295	1311	immunoreactivity	T044	C0597879
27801735	1315	1318	TCs	T025	C0597032
27801735	1322	1332	high grade	T080	C0205082
27801735	1333	1338	NSCLC	T191	C0007131
27801735	1350	1368	squamous carcinoma	T191	C0007137
27801735	1369	1378	histotype	T201	C0449574
27801735	1393	1402	low grade	T080	C1282907
27801735	1403	1409	tumors	T091	C0019638
27801735	1418	1432	adenocarcinoma	T191	C0001418
27801735	1433	1442	histology	T091	C0019638
27801735	1479	1493	IHC evaluation	T059	C1441616
27801735	1497	1502	PD-L1	T129	C4300350
27801735	1506	1511	NSCLC	T191	C0007131
27801735	1512	1528	archival tissues	T024	C0040300
27801735	1577	1594	pathology setting	T091	C0030664
27801735	1635	1648	tissue blocks	T024	C0040300
27801735	1662	1666	year	T079	C0439234